Tislelizumab in previously treated, locally advanced unresectable/metastatic microsatellite instability-high/mismatch repair-deficient solid tumorsJian Li, Lin Shen, Quanli Gao et al.|Chinese Journal of Cancer Research|2024Cited by 18
Updated analysis from a phase 2 study of tislelizumab (TIS) monotherapy in patients (pts) with previously treated, locally advanced, unresectable/metastatic microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) solid tumors.Jian Li, Lin Shen, Ye Xu et al.|Journal of Clinical Oncology|2022Cited by 2